Baxter International

Baxter International Overview

Company Headquarters: Deerfield, Illinois, US

Founded: 1931

Workforce: ~50,000

Company Working: Baxter International Inc. (Baxter) is a Fortune 500 American health care company with headquarters in Deerfield, Illinois, US. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter is a leading producer of intravenous (IV) fluids and systems. It also manufactures infusion pumps, pre-filled syringes, biological sealants, and inhaled anesthetics, as well as dialyzers and other products for the treatment of end-stage renal disease. Its global footprint and critical nature of products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. As of December 31, 2018, Baxter manufactured products in over 20 countries and sold them in over 100 countries.

Strategy

Baxter focuses on several key objectives to successfully execute its long-term strategy to achieve sustainable growth and deliver enhanced stockholder value. Its diversified and broad portfolio of medical products that treat life-threatening acute or chronic conditions and its global presence are core components of the company’s strategy to achieve these objectives. It focuses on three strategic factors as a part of its pursuit of industry-leading performance: optimizing its core portfolio globally; operational excellence focused on streamlining its cost structure and enhancing operational efficiency; and maintaining a disciplined and balanced approach to capital allocation.

Company Snapshot

$10,163M

Revenue

50,000

Employees

1931

Founded

Deerfield, Illinois, US

Headquarters

SWOT Analysis

Strengths

Diverse experience with a variety of drug categories
Worldwide manufacturing capabilities
Customized support services, including formulation development
Worldwide presence
Well-established product portfolio
Strong distribution network
Renown brand
Skilled workforce

Weaknesses

Legal complications
Limited presence in developing economies
Poor supply chain management
Maximum revenue depends on the US region

Opportunities

Strategic initiatives
Expansion of service lines
Business expansion in the healthcare segment through investments in mergers and acquisitions
New product launches
Expanding the innovation map beyond the established portfolio of products
Joint ventures with regional vendors

Threats

Volatile foreign exchange rates
Intense competition may erode the company's market share
Company may not achieve its financial goals
Government regulations for product approvals
Unfavorable reimbursement policies may hamper the business growth
Cut through competition
COVID-19 situation

Key Developments

Date	Approach	Development
February 2020	Acquisition	Baxter acquired a Seprafilm adhesion barrier from Sanofi S.A. (France). The acquired product line complements the company's leading advanced surgery portfolio.
November 2018	Product Launch	Baxter launched Tisseel Prima next-generation ergonomic syringe that enables easy control of the application of the fibrin sealant along the staple line.
March 2018	Acquisition	Baxter acquired RECOTHROM and PREVELEAK from Mallinckrodt Pharmaceuticals (Ireland) to broaden the surgical hemostat and sealant portfolio. Both products complement and broaden Baxter’s existing surgical portfolio of hemostats and sealants.
March 2016	Product Approval	Baxter received CE Mark for an expanded indication of HEMOPATCH, an innovative surgical patch, in the European Union. The new indications approved include tissue sealing and dura replacement in addition to hemostasis.

Product Offering

Baxter International
- Myasthenia Gravis
- BioSurgery
- Meningitis
- Advance Wound Care

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.